benzofurans has been researched along with Hemophilia-A* in 2 studies
2 other study(ies) available for benzofurans and Hemophilia-A
| Article | Year |
|---|---|
[Clinical management of patients with hemophilia A in nephrology: Diagnostic and therapeutic challenges illustrated by the cases of 2 patients].
Hemophilia A is an X-linked genetic hemorrhagic disorder characterized by a factor VIII deficiency. The availability of secured substitution products has led to a dramatic improvement of life expectancy in hemophiliac patients. Nowadays, adult hemophiliac patients may develop Chronic Kidney Disease (CKD) resulting from age-related comorbidities (hypertension, obesity, diabetes). In addition, the high prevalence of viral infections in this population exposes patients to an increased risk of CKD. The risk of hemorrhage in hemophiliac patients is a challenge for their clinical management, both for diagnostic procedures (kidney biopsy in particular) and for renal replacement therapy (dialysis or renal transplantation) when it is needed. This work provides an update of the literature data concerning the management of hemophiliac patients in nephrology, illustrated by the cases of two patients. Topics: Acute Kidney Injury; Antiviral Agents; Arteriovenous Shunt, Surgical; Benzofurans; Catheters, Indwelling; Diabetes Mellitus, Type 2; Drug Combinations; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nephrotic Syndrome; Quinoxalines; Renal Dialysis; Virus Replication | 2019 |
A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasma.
Oral treatment is lacking for haemophilia, the rare bleeding disorders, and some severe forms of von Willebrand's disease. We have serendipitously identified a small molecule procoagulant compound (AZ10047130). This publication describes some characteristics of AZ10047130 and a systematic search for novel hits using a, human plasma-based, high-throughput screening (HTS) assay.. Coagulation, thrombin generation, chromogenic assays and surface plasmon resonance (SPR) experiments were used to characterise AZ10047130. A 1536-well formatted human plasma coagulation assay for HTS was developed.. In the plasma clot assay (re-calcified plasma with low tissue factor) AZ10047130 shortened time to coagulation with an EC50 value of 3.9 μM (assay concentration). AZ10047130 was similarly effective in immunodepleted human and haemophilia A plasmas. SPR and chromogenic substrate experiments indicated that AZ10047130 binds to the heparin binding site of several coagulation factors. The HTS screened in excess of one million compounds. It generated some hits belonging to the same pharmacophore as AZ10047130 but also some entirely novel hits.. These novel small molecule procoagulant compounds may serve as templates for discovery of oral procoagulant drugs. Topics: Benzofurans; Blood Chemical Analysis; Blood Coagulation; Blood Coagulation Factors; Hemophilia A; Hemostasis; High-Throughput Screening Assays; Humans; Sulfonamides; Thrombin | 2013 |